Clinical trials: Patient on Antiplatelet Drugs
Drug-eluting Stent (DES)
Aspirin Mono Therapy 12-months After Drug-eluting Stents Implantation
The purpose of this study is to determine whether high dose statin therapy in patients with aspirin mono antiplatelet therapy who had received drug-eluting stent (DES) previously and were free of the adverse cardiac events during…
- Trial name
- statin (NCT01557075)
- Testing
- Atorvastatin (High dose statin treatment), Pravastatin (High dose statin treatment)
- Where
- South Korea
- Volunteers
- 2,000 people
- Sponsor
- Yonsei University
OGD, Gastric Ulcer Induced by Anti-platelet Agent
Effect of Second-look Endoscopy on Peptic Ulcer Rebleeding in Patients With Early Resumption of Antiplatelet Agents
OBJECTIVES: Up to 15% of patients with peptic ulcer bleeding will develop rebleeding, mainly in those with ulcers of higher-risk stigmata (i.e. Forrest class Ia to IIb).
- Conditions
- OGD, Gastric Ulcer Induced by Anti-platelet Agent, Duodenal Ulcer Induced by Anti-platelet Agent
- Trial name
- NCT02840929
- Testing
- Second-look OGD, Esomeprazole
- Where
- 2 sites in China, Hong Kong
- Volunteers
- 2 people
- Sponsor
- The University of Hong Kong
Coronary Artery Disease, Coronary Artery Bypass Graft
Tranexamic Acid in On-pump CABG With Premature Clopidogrel Cessation
The use of platelet aggregation inhibitors, including aspirin and clopidogrel, has become a standard management strategy for patients with acute coronary syndrome.
- Trial name
- NCT01596738
- Testing
- Tranexamic Acid, Saline
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Li Lihuan
Acute Myocardial Infarction
Effectiveness of Intracoronary Injection of Eptifibatide in Primary Coronary Intervention in STEMI Patients
The achievement of high local concentration of Eptifibatide, a GP 2b3a inhibitor,via direct intracoronary injection, promotes (in vitro) clot disaggregation.
- Trial name
- ICE (NCT00945308)
- Testing
- Eptifibatide
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Assaf-Harofeh Medical Center
Myocardial Ischemia, Hemorrhage
Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings
A single-center, randomized trial of admitted patients with ischemic heart disease receiving percutaneous coronary intervention and stent implantation will be conducted at University Hospital of Ferrara.
- Conditions
- Myocardial Ischemia, Hemorrhage, Quality of Life, Platelet Aggregation Inhibitors
- Trial name
- BATMAN (NCT02554006)
- Testing
- good clinical practice, bundle group
- Where
- Italy
- Volunteers
- 448 people
- Sponsor
- University Hospital of Ferrara
Atrial Fibrillations, Heart Valve Prostheses
What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.
The optimal antithrombotic therapy for patients with atrial fibrillation (AF) with a CHA2DS2-VASc score ≥1 with concomitant acute coronary syndrome (ACS) or revascularisation by percutaneous coronary intervention (PCI) with…
- Conditions
- Atrial Fibrillations, Heart Valve Prostheses, Acute Coronary Syndromes, Coronary Artery Diseases
- Trial name
- WOEST 2 (NCT02635230)
- Testing
- Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin.
- Where
- 9 sites in Belgium, Netherlands
- Volunteers
- 2,200 people
- Sponsor
- R&D Cardiologie
Oral Antiplatele, Anticoagulant Drugs
Effect of Oral Antiplatelet or Anticoagulant Drugs on Postoperative Bleeding Risk and Venous Closure Rate in Patients With Lower Extremity Varicose Veins After Radiofrequency Ablation
This observational study aims to assess the effect of oral antiplatelet or anticoagulant drugs on key postoperative outcomes in patients with lower extremity varicose veins who have undergone radiofrequency ablation.
- Conditions
- Oral Antiplatele, Anticoagulant Drugs, Lower Extremity Varicose Veins, Radiofrequency Ablation
- Trial name
- NCT07208695
- Testing
- Antiplatelet or Anticoagulant Drugs
- Volunteers
- 40 people
- Sponsor
- Chengdu University of Traditional Chinese Medicine
Obscure Gastrointestinal Bleeding, Iron-Deficiency Anemia
Endoscopic Evaluation for Iron Deficiency Anemia in Patients on Antithrombotic Therapy
This is a single-center, randomized pilot study evaluating the feasibility and safety of two management strategies for patients on antithrombotic therapy who present with obscure gastrointestinal bleeding (OGIB).
- Conditions
- Obscure Gastrointestinal Bleeding, Iron-Deficiency Anemia, Antithrombotic Therapy
- Trial name
- BEACON-IDA (NCT07089030)
- Testing
- Standard endoscopic evaluation, Conservative Medical Management
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec
Pre-diabetes
Resveratrol and First-degree Relatives of Type 2 Diabetic Patients
The main objective of the study is to investigate if resveratrol supplementation can improve overall and muscle-specific insulin sensitivity in first-degree relatives of type 2 diabetic patients.
- Trial name
- NCT02129595
- Testing
- resveratrol
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Maastricht University Medical Center
Acute Coronary Syndrome (ACS), High Bleeding Risk (HBR)
Optimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy
Study Purpose Coronary heart disease (CAD) is a leading global cause of death, with Acute Coronary Syndrome (ACS) as its acute and life-threatening subtype.
- Conditions
- Acute Coronary Syndrome (ACS), High Bleeding Risk (HBR), Coronary Artery Disease (CAD)
- Trial name
- NCT07354828
- Where
- China
- Volunteers
- 3,500 people
- Sponsor
- Shenyang Northern Hospital
Chronic Kidney Disease
Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study
Higher coronary in-stent thromboses and bleeding complications on anti-platelet agents are more common in Chronic Kidney Disease vs. non-Chronic Kidney Disease patients.
- Trial name
- WiCKDonASA (NCT01768637)
- Testing
- Aspirin, Clopidogrel
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Bleeding, Tachycardia
Effect of Desmopressin on Platelet Function in CKD Patients on Antiplatelet Drug
Prolonged Collagen/Epinephrine - closure time (CEPI-CT) indicates platelet dysfunction in CKD patients taking antiplatelet agent.
- Conditions
- Bleeding, Tachycardia, Dyspnea
- Trial name
- NCT01841515
- Testing
- Desmopressin administration
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- University of Ulsan
Tinnitus
A Study on the Effect of Cilostazol in Patients With Chronic Tinnitus
1. Overview of tinnitus Tinnitus is a noisy sound which is perceived without any external sound source. According to the survey of the US, 10-20% of adult have the symptom of tinnitus and 3-5% of tinnitus patients have severe…
- Trial name
- CITI-ESR (NCT01378650)
- Testing
- Cilostazol
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Jong Woo Chung
Coronary Artery Disease, Chest Pain
The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization
This study will explore the effect of clopidogrel on coated-platelets in patients who are given a loading dose before diagnostic catheterization or percutaneous coronary intervention.
- Trial name
- NCT00644657
- Testing
- Clopidogrel
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Oklahoma
Drug Effect Disorder, Platelet Procoagulant Activity Deficiency
the Effect Between Platelet Reactivation and Antiplatelet Drugs
Different antiplatelet drugs played various role in coronary artery disease. The mechanisms were unclear. Platelet reactivation maybe was one of major causes.
- Trial name
- NCT02198053
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Beijing Anzhen Hospital
Coronary Artery Disease
Impact of Ticagrelor Re-load on Pharmacodynamic Profiles
Platelets are parts of your blood that stick together to help form a clot. The stickier your platelets are, the greater your chance of having a heart attack. A clot in the wrong place can lead to a heart attack or stroke.
- Trial name
- NCT01731041
- Testing
- Ticagrelor 180mg, Ticagrelor 90mg
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Florida
Hip Fracture
Hip-Fracture Surgery on Patients in Clopidogrel Therapy
Patients in Clopidogrel therapy alone or in combination with acetylsalicylic acid (Dual Antiplatelet Therapy (DAPT) presenting with a hip-fracture represent the surgeon with the dilemma of putting the patient at risk of a major…
- Trial name
- NCT02391883
- Testing
- Clopidogrel
- Volunteers
- 356 people
- Sponsor
- Hvidovre University Hospital
Von Willebrand Diseases, Major Constitutional Thrombopathy
Development of a Device for Evaluating Primary Hemostasis Under Whole Blood Flow Conditions
Currently, the exploration of primary hemostasis (a physiological phenomenon used to stop bleeding) is imperfect because it is based on targeted tests for platelets or von Willebrand factor, without taking into account blood flow…
- Conditions
- Von Willebrand Diseases, Major Constitutional Thrombopathy, Patient on Antiplatelet Drugs
- Trial name
- INDONESIA (NCT03773159)
- Testing
- Blood sampling
- Where
- 2 sites in France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
Coronary Artery Disease
Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation
Early stent thrombosis has been noted with increased frequency in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) who are treated with bivalirudin and clopidogrel.
- Trial name
- NCT01789814
- Testing
- Prasugrel, Clopidogrel
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Tufts Medical Center
Coronary Artery Occlusive Disease
The Effect of 6% Hydroxyethyl Starch 130/0.4 on Blood Loss and Coagulation in Patients Medicated With Antiplatelet Agents Prior to Off-Pump Coronary Bypass Graft Surgery
HES 130/0.4 significantly solution will not affect on coagulation and blood loss in patients medicated with antiplatelet agents prior to off-pump coronary bypass surgery (OPCAB).
- Trial name
- NCT01051206
- Testing
- 6% hydroxyethyl Stach 130/0.4
- Where
- South Korea
- Volunteers
- 106 people
- Sponsor
- Yonsei University